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Objective: The standard dose of depot gonadotropin releasing hormone agonist (GnRHa) may be too
much to prevent premature luteinizing hormone (LH) surge in controlled ovarian stimulation (COS). The
purpose of this study was to ﬁnd out the minimal effective dose of Leuplin depot to prevent premature
LH surge in patients undergoing intrauterine insemination (IUI).
Materials and Methods: From January 2006 to December 2007, unexplained infertile patients who were
going to undergo IUI were recruited into the study. They were assigned sequentially to one of the
following treatment groups. The ﬁrst 50 patients received the 1/3-dose of Leuplin depot in the midluteal
phase of the cycle preceding COS. If no premature LH surge occurred in the 50 patients, the study was
continued with 1/4-dose of Leuplin depot in the subsequent 50 patients. Similarly, if no premature LH
surge occurred with 1/4 dose, the study was continued with 1/5-dose of Leuplin depot in the following
50 patients. Ovarian stimulation was started with human menopausal gonadotropin (hMG) at 112.5 IU/
d after downregulation, then IUI was performed 36 hours after human chorionic gonadotropin (hCG)
injection.
Results: Premature LH surge was effectively prevented with 1/3-dose and 1/4-dose of Leuplin depot.
Premature LH surge occurred in three of the 50 patients (6%) in the 1/5-dose group. The patients in the 1/
4-dose group received a signiﬁcantly lower amount of hMG and fewer days of COS, compared with the 1/
3-dose group.
Conclusion: The 1/4 dose of Leuplin depot is the minimal effective dose to prevent premature LH surge.
Further trial is worthwhile to compare the reducing dose Leuplin depot and daily low-dose leuprolide in
in vitro fertilization (IVF) programs.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
The beneﬁts of using gonadotropin releasing hormone agonists
(GnRHa) in women who received controlled ovarian stimulation
(COS) in assisted reproductive treatment are well documented,and Gynecology, Shin Kong
Road, Shih Lin District, Taipei
).
bstetrics & Gynecology. Published bsuch as prevention of premature luteinizing hormone (LH) surge
and a lower cancellation rate [1]. Among the various types of
GnRHa protocols, the long protocol is the most popularly used
nowadays. There are two modes of GnRHa administration in the
long protocol; the daily low-dose or the single-dose depot injec-
tion. Depot GnRHa formulations have been welcomed by both pa-
tients and physicians, because of the convenience of single
administration. The major concern of depot GnRHa is excessive
suppression of pituitary function, which in turn may inﬂuence
pregnancy outcomes, duration of COS, and amount of gonadotropiny Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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Figure 1. Serum luteinizing hormone (LH) values (mean ± standard deviation) in 1/3-,
1/4-, and 1/5-dose Leuplin depot groups relative to the day of human chorionic
gonadotropin (hCG) injection (D0). D ¼ day.
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of depot GnRHa is still enough to prevent premature LH surge in
in vitro fertilization (IVF) treatment. Half-dose depot leuprolide
acetate [2e4] or 1/2-dose depot triptorelin [5,6] has been reported
to result in similar clinical outcomes, including prevention of pre-
mature LH surge, compared with a daily low-dose GnRHa long
protocol.
In a recent Cochrane review, no signiﬁcant differences were
detected between the single-dose depot protocol and daily low-
dose GnRHa long protocol in the clinical outcomes of IVF,
including live birth/ongoing pregnancy rates, clinical pregnancy
rate, as well as number of oocytes retrieved, miscarriage rate,
multiple pregnancy rate, and rate of severe ovarian hyperstimula-
tion syndrome [7]. This Cochrane review included randomized,
controlled trials comparing depot (using either full-dose or 1/2-
dose) and a daily low-dose GnRHa long protocol in IVF treatment.
However, excessive pituitary suppression by depot GnRHa (using
either full-dose or 1/2-dose) resulted in more gonadotropin con-
sumption and a longer duration of ovarian stimulation [7], which
may increase the overall cost of IVF treatment.
The 1/3-dose depot triptorelin has been shown to effectively
prevent premature LH surge in IVF cycles [8]. However, the dura-
tion of COS and amount of gonadotropin consumption showed a
trend of lower, but nonsigniﬁcant decrease [8]. Whether or not
further decreasing the dose of depot GnRHa is still effective for the
prevention of premature LH surge is not known. Furthermore, the
minimal dose of depot GnRHa to prevent premature LH surge has
not yet been determined. Utilizing the minimal dose of depot
GnRHa can potentially reduce the amount and duration of gonad-
otropin stimulation.
The purpose of this study was to ﬁnd out the minimal effective
dose of Leuplin depot (leuprolide acetate 3.75 mg; Takeda, Osaka,
Japan) required to prevent premature LH surge in patients un-
dergoing COS. For fear of premature LH surge that compromised
the IVF outcomes, we performed a pilot study in patients un-
dergoing intrauterine insemination (IUI) before application to the
IVF program. The logic behind this was that insemination time
could be advanced if premature LH surge occurred in an IUI cycle.
If a particular dose of depot GnRHa failed to prevent premature
LH surge in IUI, it would not be worth testing it further in IVF
cycles.
Materials and methods
This prospective observational study was approved by the
Institutional Review Board of Shin Kong Wu Ho-Su Memorial
Hospital, Taipei, Taiwan. All patients entered this study only after
informed written consent was obtained. Patients with unexplained
infertility who were going to receive COS/IUI were recruited for the
study. The inclusion criteria were female aged < 38 years old, with
regular menstrual cycles ranging from 21 days to 35 days, body
mass index ranging from 18 kg/m2 to 29 kg/m2, normal ovarian
function as detected by basal serum follicle-stimulating hormone
and estradiol (E2), normal hysterosalpingography, normal semen
parameter, and no history of ovarian or tubal surgery. Assuming
that 20% of patients will have premature LH surge with gonado-
tropin only and 2% of patients will have premature LH surge with
gonadotropin and GnRHa [9], 50 cases were needed in the study
group to have a power of 0.8 (a ¼ 0.05, b ¼ 0.2). Only patients who
complied with all selection criteria were assigned sequentially to
one of the treatment groups, starting from the 1/3-dose of Leuplin
depot. If no premature LH surge occurred with the 1/3 dose in the
ﬁrst 50 patients, the study was continued with decreasing doses for
the subsequent 50 patients (1/4 dose in the second group and 1/5
dose in the third group).Pituitary desensitization was achieved with a speciﬁc dose of
Leuplin depot in a single subcutaneous injection in the midluteal
phase (Day 21) of the menstrual cycle preceding treatment. Serum
E2, LH, and progesterone levels were measured 16 days after Leu-
plin depot injection. The criteria of pituitary desensitization was
deﬁned as serum E2 level < 50 pg/mL and LH level < 5 mIU/mL. If
pituitary desensitization was not achieved, blood sampling was
repeated every 3 days until pituitary desensitization. Ovarian
stimulation with human menopausal gonadotropin (hMG, Mer-
ional; IBSA, Lamone, Switzerland) 112.5 IU/d was prescribed for
6 days and then the dose was adjusted according to ovarian
response. Human chorionic gonadotropin (hCG, Ovidrel; Merk-
Serono, Modugno, Italy) 250 mg was given when two follicles
reached 18 mm in diameter. IUI was performed 36 hours later.
Serum concentrations of LH, E2, and progesterone were measured
daily from Day 4 of hMG stimulation until the day of hCG admin-
istration. If premature LH surge was detected, IUI was arranged on
two occasions on the next 2 consequent days after hCG adminis-
tration. Premature LH surge is deﬁned as LH level> 10mIU/mLwith
progesterone elevation > 1 ng/mL before leading follicles reached
18 mm [10]. The primary outcome measure was the percentage of
premature LH surge. The secondary outcome measures were the
ampoules of hMG used and the pregnancy rates.Results
From January 2006 to December 2007, 150 patients were
included in this study. No premature LH surge occurred in the ﬁrst
50 patients who received the 1/3-dose of Leuplin depot. The next
50 patients were assigned to the 1/4-dose group. This lower dose
also was able to prevent premature LH surge and to maintain
constantly low serum LH concentrations during the follicular phase
(Figure 1). In accordance with the study protocol, the subsequent
50 patients received the 1/5-dose of Leuplin depot. The serum LH
level was still maintained at a low level during the follicular phase
(Figure 1). However, premature LH surge occurred in three patients
(6%, Figure 2). Because of the high incidence of premature LH surge,
the study was stopped here without further lowering the Leuplin
dose. The outcomes of the 1/3-dose, 1/4-dose, and 1/5-dose groups
are shown in Table 1. Compared with the 1/3-dose group, patients
in the 1/4-dose group and 1/5-dose group required a signiﬁcantly
lower amount of hMG and fewer days of hMG stimulation. There
were no signiﬁcant differences in hMG amount required and days
of hMG stimulation between the 1/4-dose group and the 1/5-dose
group. Mean serum E2, LH, and progesterone levels on the day of
hCG injection were similar between the three groups. The preg-
nancy rates and miscarriage rates were also comparable.
Figure 2. Serum luteinizing hormone (LH) values of three patients suffering from
premature LH surge in 1/5-dose Leuplin depot group. D ¼ day; hCG ¼ human chorionic
gonadotropin.
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Depot GnRHa are commonly used to treat women with endo-
metriosis or uterine ﬁbroids. This single dosing administration is
attractive for use in long downregulation protocols in IVF cycles
because of its convenience and reduced stress associated with daily
low-dose injection [11]. Assisted reproduction treatment is very
stressful to infertile couples, therefore, any simpliﬁcation in treat-
ment is welcome. In order to avoid excessive pituitary suppression
by depot GnRHa, Balasch et al [12] ﬁrst demonstrated that the 1/2-
dose depot triptorelin was enough to prevent premature LH surge.
Following that, several similar studies have been done to reduce the
dose of depot GnRHa in an attempt to lessen the degree of pituitary
suppression. However, it was shown that either full-dose or 1/2-
dose depot GnRHa resulted in a higher amount of gonadotropin
consumption and longer duration of ovarian stimulation, compared
with a daily low-dose GnRHa long protocol [7]. This implies that the
1/2-dose depot GnRHa is still too much in terms of pituitary sup-
pression. To date, only one study demonstrated the effectiveness of
the 1/3-dose of depot triptorelin in the long protocol of COS [8]. In
this prospective, randomized study comparing the 1/3-dose and 1/
2-dose depot triptorelin in IVF cycles, a lower, but not statistically
signiﬁcant, length and dose of ovarian stimulationwas found in the
group receiving the 1/3-dose depot triptorelin. The clinical preg-
nancy rates, implantation rates, and delivery rates showed no sig-
niﬁcant differences, and no premature LH surge occurred in both
groups [8]. We speculated that it may be possible to further
decrease the dose of depot GnRHa with adequate pituitary
suppression.Table 1
Results of ovarian stimulation with 1/3-, 1/4-, and 1/5-dose Leuplin depot.
Leuplin depot 1/3-dose 1/4-dose 1/5-dose
Case number 50 50 50
Age (y) 32.5 ± 3.5 32.7 ± 3.1 32.7 ± 3.3
No. of hMG
ampoules
14.5 ± 6.2 a,b 12.1 ± 5.4 a,c 11.9 ± 5.5 b,c
No. of days of
stimulation
9.8 ± 2.1 a,b 8.9 ± 2.2 a,c 8.9 ± 2.4 b,c
E2 on day of hCG
injection (pg/mL)
1251 ± 904 1090 ± 954 1100 ± 921
LH on day of hCG
injection (mIU/mL)
1.5 ± 1.4 1.5 ± 1.2 1.7 ± 1.5
Progesterone on day of
hCG injection (ng/mL)
0.96 ± 0.56 1.1 ± 1.0 1.0 ± 0.9
Pregnancy rate 20% (10/50) 20.3% (11/50) 20% (10/50)
Miscarriage rate 10% (1/10) 9% (1/11) 20% (2/10)
E2 ¼ estradiol; hCG ¼ human chorionic gonadotropin; hMG ¼ human menopausal
gonadotropin; LH ¼ luteinizing hormone.
a,b p < 0.05 by unpaired t test.
c p > 0.05 by unpaired t test.The present study showed that the 1/3-dose and 1/4-dose of
Leuplin depot was able to avoid the risk of premature LH surge in
COS during an IUI cycle. In the 1/5-dose group, premature LH surge
occurred in three of 50 patients (6%), which was unacceptable in an
IVF program. Therefore, the 1/4 dose is the minimal effective dose
of Leuplin depot to prevent premature LH surge. The study also
showed that the amount of gonadotropin consumption and the
duration of COSwere signiﬁcantly lower in the 1/4-dose group than
in the 1/3-dose group. It can be postulated that the intensity of
pituitary suppression was less with the 1/4-dose Leuplin depot.
However, the ﬁnding that 1/4-dose Leuplin depot can prevent
premature LH surge in IUI cannot be extrapolated to the IVF pro-
gram, becausemore gonadotropinwas usually used in IVF.Whether
1/4-dose Leuplin depot can prevent premature LH surge under a
higher dose of gonadotropin stimulation, as in an IVF program,
remains unknown. Further study is necessary to clarify this and
compare the clinical outcomes of 1/4-dose Leuplin depot with daily
low-dose Leuplin in a long protocol in IVF.
It may be argued that pituitary desensitization is not necessary
in IUI. The pregnancy rate of IUI ranges from 10% to 25% [13,14]. One
reason for such a low pregnancy rate is premature LH surge, which
negatively affects pregnancy rates [15]. It has been reported that
24% of IUI cycles may develop premature LH surge, resulting in
cycle cancellation or poorly planned timing of insemination. It has
been proposed to incorporate GnRH antagonists into IUI cycles to
prevent premature LH surge [16]. The use of GnRH agonists and
antagonists in IUI cycles reduces the risk of premature LH surge and
improves pregnancy rates in patients with previously failed IUI
[17,18]. The present study showed for the ﬁrst time that 1/4-dose
Leuplin depot was effective to prevent LH surge in IUI cycles.
However, it may needmore case numbers and detection of LH surge
twice daily to conﬁrm this study result. Compared with the GnRH
antagonist protocol, depot GnRHa reduces the injection burden of
patients and is therefore more patient friendly.
In conclusion, we report the ﬁrst dose-ﬁnding study of Leuplin
depot for prevention of premature LH surge. We demonstrate that
1/4-dose Leuplin depot is the minimal effective dose for the pre-
vention of premature LH surge in IUI. More case numbers and the
detection of LH surge twice daily are required to prove this result.
Further studies are warranted to compare the 1/4-dose and daily
low-dose GnRHa in IVF programs, and their effects on the length
and dose of ovarian stimulation.
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